Clinical Trial: First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.

U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06840782) titled 'First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.' on Jan. 16.

Brief Summary: First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study

Study Start Date: Feb., 2025

Study Type: INTERVENTIONAL

Condition: Oligometastatic Non-small Cell Lung Cancer (NSCLC)

Intervention: RADIATION: Radical local treatment

RLT of all metastatic sites. The possible RLT options will be SBRT, interventional radiology and/or minimally inva...